Thanks Tada. That absolute risk reduction of 3.2% and NNT of 31 refers to a 4-point MACE endpoint (first adjudicated CV death or non-fatal MI, stroke, or hospitalization for heart failure). As I mentioned in my earlier post, one needs to match endpoints and patient population for a fair comparison of NNTs across drugs and trials.
BDAZ